Finanzas de Moderna Inc (MRNA)MRNAModerna Inc

Moderna, Inc. (MRNA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is COVID, accounting for 96.8% of total sales, equivalent to $91.00M. Another important revenue stream is RSV. Understanding this composition is critical for investors evaluating how MRNA navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Moderna, Inc. maintains a gross margin of 64.14%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -533.79%, while the net margin is -539.31%. These profitability ratios, combined with a Return on Equity (ROE) of -39.00%, provide a clear picture of how effectively MRNA converts its operational activities into shareholder value.

In the context of the broader market, MRNA competes directly with industry leaders such as NTRA and ARGX. With a market capitalization of $80.90B, it holds a leading position in the sector. When comparing efficiency, MRNA's gross margin of 64.14% stands against NTRA's 63.70% and ARGX's 90.41%. Such benchmarking helps identify whether Moderna, Inc. is trading at a premium or discount relative to its financial performance.

Moderna's financial performance shows a troubling trend with net income losses consistently reported, including a loss of $1.34 billion in Q1 2026 and $782 million in Q2 2026. The gross margin has also fluctuated significantly, with a negative gross margin of -135.73% in Q1 2026, indicating operational challenges.